Cancer pain occurs due to the unregulated growth of cancerous cells that can compress or invade nearby nerves and organs. Cancer pain therapeutics include opioids, non-opioids, nerve blockers, etc. that help in relieving cancer pain by inhibiting pain signals. Opioids like morphine are considered the first line of treatment while non-opioid analgesics and nerve blocks are recommended along with opioids for more effective pain relief.
The cancer pain market is estimated to be valued at USD 7.21 Bn in 2024 and is expected to reach USD 10.35 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
Key Takeaways
operating in the cancer pain therapeutics market include Pfizer, Teva Pharmaceuticals, Purdue Pharma, Mallinckrodt Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, and Mylan.
Increasing cancer prevalence has augmented the demand for effective cancer pain management therapies globally. Technological advancements such as advanced drug delivery systems and minimally invasive techniques aid in improving the efficacy of cancer pain therapeutics.
Growing demand is attributed to increasing Cancer Pain Market rates owing to lifestyle changes, growing elderly population, and exposure to carcinogens. According to WHO, cancer burden has risen to 19.3 million cases and 10 million deaths in 2020. Furthermore, advancement in treatment modalities has increased cancer survival rates thereby augmenting the need for controlling cancer pain. Improved formulations such as long-acting and abuse-deterrent opioids along with patient support programs have made cancer pain management more effective.
Market Trends
The shift from opioids to non-opioid and multi-modal therapies is a key trend witnessed in the market. This is due to increasing awareness about risks associated with opioid overuse and growing preference for minimally invasive techniques. Emergence of novel drug classes such as cannabinoids, tramadol, and capsaicin are supplementing traditional therapies.
Combination of pharmacologic and non-pharmacologic approaches is gaining popularity for its synergistic effect. Integration of therapies such as exercise, psychological counseling, and nerve blocks with pharmaceuticals provide enhanced pain relief with fewer side effects.
Market Opportunities
Untapped emerging markets like India, Brazil and Africa present lucrative growth opportunities owing to increasing healthcare spending and cancer burden in these regions. Furthermore, development of biologics targeting specific pain pathways can further expand the market scope. Growing focus on personalized pain medicine based on genetic and neurological evaluation offers new avenues.
Impact of COVID-19 on Cancer Pain Market Growth
The COVID-19 pandemic has significantly impacted the cancer pain market. During the initial lockdown phases of 2020-21, there was a reduction in demand as routine checkups, elective surgeries, and treatments were postponed. This had a sharp negative influence on the market size. However, cancer being a life-threatening disease, urgent treatments continued with strict safety protocols.
With relaxations in restrictions in 2021, the market saw a revival as postponed procedures resumed. But challenges remained in terms of managing cancer pain for positive patients and those undergoing radiation or chemotherapy amid the pandemic stress. Telehealth and telemedicine emerged as reliable options to ensure continuity of care and pain management consultations without risk of viral exposure. Overall, the pandemic emphasized the need for affordable and accessible pain relief options to support cancer patients worldwide.
Going forward, the market is expected to regain momentum in line with resumption of diagnostic and treatment services. At the same time, it will be important to consider aspects like potential supply chain disruptions, prioritizing vulnerable patients, and integrating digital solutions for remote monitoring and support. Adopting a structured and balanced pandemic response focusing on both physical and mental health of cancer warriors will be a key determinant of future growth patterns.
Geographically, North America holds the major share in the cancer pain market, led by the US which has witnessed high incidence of various cancers and focus on palliative care. The Asia Pacific region is projected to grow at the fastest rate owing to rising Cancer prevalence, increasing healthcare expenditures, and growing medical tourism. Countries like China and India which are experiencing economic development and higher health awareness present lucrative opportunities.
Some of the key market players globally include Pfizer, Inc., Purdue Pharma, Medtronic Plc, Allergan, Pharma, and Baxter International Inc. In terms of competitive strategies, companies are focused on product innovation, partnerships, and expanding access to therapies especially in developing regions.
Get more insights on - Cancer Pain Market
Get this Report in Japanese Language: がんの痛み市場
Get this Report in Korean Language: 암 통증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
